BOLD vs. ALEC, CCCC, TSHA, FATE, HUMA, EXAI, EDIT, VALN, ALVO, and ALLO
Should you be buying Audentes Therapeutics stock or one of its competitors? The main competitors of Audentes Therapeutics include Alector (ALEC), C4 Therapeutics (CCCC), Taysha Gene Therapies (TSHA), Fate Therapeutics (FATE), Humacyte (HUMA), Exscientia (EXAI), Editas Medicine (EDIT), Valneva (VALN), Alvotech (ALVO), and Allogene Therapeutics (ALLO). These companies are all part of the "medical" sector.
Alector (NASDAQ:ALEC) and Audentes Therapeutics (NASDAQ:BOLD) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, dividends, community ranking, institutional ownership, risk, valuation, media sentiment, earnings and analyst recommendations.
Audentes Therapeutics has lower revenue, but higher earnings than Alector. Alector is trading at a lower price-to-earnings ratio than Audentes Therapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, Alector had 1 more articles in the media than Audentes Therapeutics. MarketBeat recorded 1 mentions for Alector and 0 mentions for Audentes Therapeutics. Audentes Therapeutics' average media sentiment score of 0.06 beat Alector's score of 0.00 indicating that Alector is being referred to more favorably in the media.
Audentes Therapeutics has a net margin of 0.00% compared to Audentes Therapeutics' net margin of -134.34%. Alector's return on equity of 0.00% beat Audentes Therapeutics' return on equity.
Alector presently has a consensus price target of $14.50, suggesting a potential upside of 176.19%. Audentes Therapeutics has a consensus price target of $23.00, suggesting a potential upside of 108.52%. Given Audentes Therapeutics' higher possible upside, analysts clearly believe Alector is more favorable than Audentes Therapeutics.
Audentes Therapeutics received 326 more outperform votes than Alector when rated by MarketBeat users. Likewise, 69.22% of users gave Audentes Therapeutics an outperform vote while only 60.25% of users gave Alector an outperform vote.
85.8% of Alector shares are owned by institutional investors. Comparatively, 96.3% of Audentes Therapeutics shares are owned by institutional investors. 14.0% of Alector shares are owned by insiders. Comparatively, 5.3% of Audentes Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Alector has a beta of 0.79, indicating that its share price is 21% less volatile than the S&P 500. Comparatively, Audentes Therapeutics has a beta of 2.18, indicating that its share price is 118% more volatile than the S&P 500.
Summary
Audentes Therapeutics beats Alector on 9 of the 17 factors compared between the two stocks.
Get Audentes Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for BOLD and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BOLD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Audentes Therapeutics Competitors List
Related Companies and Tools
